On November 19, 2022, Melinda Griffith notified the Board of Directors (the Board) of Oncocyte Corporation (the Company) of her resignation from the Board, effective January 1, 2023. Ms. Griffith is the Chair of the Nominating/Corporate Governance Committee of the Board and a member of the Sciences and Technology Committee of the Board. Ms. Griffith's resignation was not due to any disagreement with respect to the Company's operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.76 USD | +1.10% |
|
+0.73% | +10.40% |
06-03 | Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial | CI |
05-30 | Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.40% | 36.89M | |
-43.39% | 7.73B | |
+11.68% | 3.7B | |
-21.21% | 1.99B | |
-23.77% | 1.6B | |
+14.81% | 999M | |
+18.25% | 739M | |
-10.04% | 685M | |
-36.12% | 461M | |
-4.47% | 279M |
- Stock Market
- Equities
- OCX Stock
- News OncoCyte Corporation
- Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023